Alirocumab(TD-HV275016) is a research-grade recombinant antibody targetingProprotein convertase subtilisin/kexin type 9. Produced in mammalian cells with native-like glycosylation.HighlightsResearch Grade— For PK/PD studies, assay development, and ADA research.Native Glycosylation— Mammalian expression ensures native-like patterns.
Species reactivity
Human
Applications
ELISA, Bioactivity: FACS, Functional assay, Research in vivo
Protein A/G purified from cell culture supernatant.
Accession
Q8NBP7
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C.
Alternate Names
REGN727, SAR-236553, 1245916-14-6
Background
Frovocimab (LY3015014) (INN) is a monoclonal antibody designed for the treatment of hypercholesterolemia.This drug is being developed by Eli Lilly and Company.
Caption
Flow-cytometry using anti-human PCSK9 antibody. Jurkat cells were fixed and permeabilized, then stained with an irrelevant antibody (Blue Histogram) or an anti-human PCSK9 monoclonal antibody (Catalog HV275016, Yellow Histogram) at a concentration of 5 µg/ml for 30 mins at RT. After washing, bound antibody was detected using Goat Anti-Human IgG H&L Polyclonal Antibody, FITC (abinScience: HF690414) and cells analysed on a NovoCyte Flow Cytometer. | SDS-PAGE for Research Grade Alirocumab. | Detects Human PCSK9 in indirect ELISAs.Immobilized Human PCSK9, His Tag (Catalog No:TD-HV275011) at 1 μg/mL (100 μL/well) on an Anti-His antibody (Catalog No:TD-YP205015) Coated plate can bind Human PCSK9 Mab
Note
For research use only. Not suitable for clinical or therapeutic use.